This project was funded by Zambon S.A.U.D.S.G., M.B.-E., J.K., F.P.-E., F.V., M.-R.L. and J.P. declare no conflict of interest.
M.C. has received honoraria for lecturing or advisory boards from AbbVie, Bial and Zambon. F.E.-S.
has received honoraria as a speaker, support to attend scientific meetings and grants for conducting
studies from Abbvie, Bial, Boston Scientifice, Medtronic, Merz Pharma, Teva, UCB Pharma and
Zambon. E.F. has received advisory, consulting and lectures fees from Abbvie, Teva, Bial, Zambon
and Neuraxpharm. For P.J.G.R., no specific funding was received for this study. The author reports
no conflicts of interest. In the previous 12 months, this author received research support from Aller gan and UCB, personal compensation as a consultant/scientific advisory boards from Italfarmaco,
Britannia, Bial and Zambon and speaking honoraria from Italfarmaco, Zambon, Allergan and Abbvie.
F.G. received grants from the Instituto de Salud Carlos III and from the European Commission
(Horizon 2020). He received consulting honoraria from Exeltis and for lecturing from Zambon and
TEVA. L.L.-M. has received compensated advisory services, consulting, research grant support, or
speaker honoraria from AbbVie, Acorda, Bial, Intec Pharma, Italfarmaco, Pfizer, Roche, Teva, UCB
and Zambon. J.C.M.C. has received honoraria as a speaker from Abbvie, Allergan, Bial, Boehringer
Ingelheim, GSK, Krka Farmaceutica, Merz Pharma, Ipsen, Italfarmaco, Lundbeck, Medtronic, TEVA,
UCB and Zambon; research grants from Abbvie, Allergan, Merz Pharma, Italfarmaco, Lundbeck,
UCB and Zambon; and participated in the advisory boards of Abbvie, Allergan, GSK, Bial, Merz
Pharma, Merck, Boehringer Ingelheim, Ipsen, Italfarmaco, Lundbeck, Orion, UCB and Zambon.
P.M. has received support for attending meetings and/or honorarium for lecturing from Abbott,
Allergan, Abbvie, Bial, Britannia, Italfarmaco, Merz, UCB, Roche, Teva and Zambon. J.M.S. has
participated in advisory boards and pharmaceutical industry-sponsored symposia for Zambon, UCB,
Bial, Italfarmaco, Eisai España and Abbvie Spain. B.T.: speaking fees, AbbVie, and travel expenses,
Italfarmaco. R.Y. has received honoraria as a speaker for Bial, Italfarmaco, Teva and Zambon, support
to attend scientific meetings from Alter, for consultancy from Bial, and sponsored for conducting
studies from Zambon and Lundbeck. A.A. is employed and receives personal fees from Zambon.Parkinson's disease (PD) is a chronic progressive and irreversible disease and the second most common neurodegenerative disease worldwide. In Spain, it affects around 120.000-150.000 individuals, and its prevalence is estimated to increase in the future. PD has a great impact on patients' and caregivers' lives and also entails a substantial socioeconomic burden. The aim of the present study was to examine the current situation and the 10-year PD forecast for Spain in order to optimize and design future management strategies. This study was performed using the modified Delphi method to try to obtain a consensus among a panel of movement disorders experts. According to the panel, future PD management will improve diagnostic capacity and follow-up, it will include multidisciplinary teams, and innovative treatments will be developed. The expansion of new technologies and studies on biomarkers will have an impact on future PD management, leading to more accurate diagnoses, prognoses, and individualized therapies. However, the socio-economic impact of the disease will continue to be significant by 2030, especially for patients in advanced stages. This study highlighted the unmet needs in diagnosis and treatment and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.PfizerRocheTeva Pharmaceutical IndustriesUCBEuropean CommissionInstituto de Salud Carlos IIIHorizon 202
